2024 - Comparability of Five Alternative AAV9 Downstream Processes, from Ultracentrifugation to Chromatography
Date2024-06-27
Deadline2024-06-27
VenueONLINE-VIRTUAL, USA - United States
KeywordsLife Sciences; Pharma Manufacturing & Supply Chain; Drug Discovery & Development
Topics/Call fo Papers
Improved analytical methods are helping improve the understanding of capsid heterogeneity in adeno-associated virus (AAV) therapeutic preparations. This understanding allows the development of manufacturing processes that produce AAV therapeutics with fewer non-functional capsids.
In this webinar, the speakers will present the results of a five-arm AAV9 comparability protocol that includes four alternative two-column downstream processes at 50-L scale and an ultracentrifugation (UC) process at 200-L scale. The UC process is the gold standard for functional capsid purification.
The expert speakers will outline simplified processes for both the capture and the empty/full (E/F) separation steps, including various combinations of cation exchange chromatography (CEX) and anion exchange chromatography (AEX) monoliths with different gradient types, as well as a process using an affinity resin and AEX monolith.
Read more...
Register for this webinar today to gain insights into the production of AAV therapeutics using enhanced analytical methods with their role in reducing capsid heterogeneity.
Keywords: Drug Development, Analytical Testing, Commercial Manufacturing, Bioanalytical Testing, AAV, Viral Vector, Viral Vector Manufacturing, Cell & Gene Therapies, AAV Manufacturing, CDMO/CMO, Quality, AAV Capsid
In this webinar, the speakers will present the results of a five-arm AAV9 comparability protocol that includes four alternative two-column downstream processes at 50-L scale and an ultracentrifugation (UC) process at 200-L scale. The UC process is the gold standard for functional capsid purification.
The expert speakers will outline simplified processes for both the capture and the empty/full (E/F) separation steps, including various combinations of cation exchange chromatography (CEX) and anion exchange chromatography (AEX) monoliths with different gradient types, as well as a process using an affinity resin and AEX monolith.
Read more...
Register for this webinar today to gain insights into the production of AAV therapeutics using enhanced analytical methods with their role in reducing capsid heterogeneity.
Keywords: Drug Development, Analytical Testing, Commercial Manufacturing, Bioanalytical Testing, AAV, Viral Vector, Viral Vector Manufacturing, Cell & Gene Therapies, AAV Manufacturing, CDMO/CMO, Quality, AAV Capsid
Other CFPs
- Asking the Right Questions: How the Patient Perspective Impacts the Success of Rare Disease Studies
- Future of Chromatography Resins: Improved Resolution in Bioprocessing
- Future of Bioprocessing: Bioprocessing 4.0 and Cloud Computing
- ECOA Licensing & Screenshot Review: Best Practices for Faster Approvals
- Intersection of Quality and Operations — A Strategy for Clinical Quality Assurance
Last modified: 2024-06-12 05:13:30